hydroxychloroquine has been researched along with Erythremia in 1 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rotenberg, C | 1 |
| Besnard, V | 1 |
| Brillet, PY | 1 |
| Giraudier, S | 1 |
| Nunes, H | 1 |
| Valeyre, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells[NCT04751279] | 80 participants (Anticipated) | Observational | 2021-03-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for hydroxychloroquine and Erythremia
| Article | Year |
|---|---|
Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia.
Topics: Adrenal Cortex Hormones; Biopsy; Female; Humans; Hydroxychloroquine; Janus Kinase 2; Middle Aged; Mu | 2018 |